About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Study of Mirogabalin for Central Neuropathic Pain | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 3NCT03901352

Study of Mirogabalin for Central Neuropathic Pain

Investigate the efficacy and safety of mirogabalin in participants with central neuropathic pain in comparison to placebo

Lead sponsor: Daiichi Sankyo Co., Ltd.•118 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Daiichi Sankyo Co., Ltd.

\[Double Blind Phase\] The primary objective is to compare change in the Average Daily Pain Score (ADPS) from baseline to Week 14 in Asian participants with central neuropathic pain (central neuropathic pain after spinal cord injury) receiving mirogabalin versus placebo. \[Open Extension Phase\] The objective is to assess the long-term safety and efficacy of mirogabalin in participants with central neuropathic pain (central neuropathic pain after spinal cord injury, central post stroke pain, and central neuropathic pain in Parkinson's disease).

Age

20 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Spinal cord injury (SCI) due to trauma
•American Spinal Injury Association impairment scale A, B, C, or D

Exclusion Criteria

•Other severe pain at screening or randomization, unrelated to central neuropathic pain after SCI, that may confound the assessment of central neuropathic pain after SCI
•Neurologic disorders at screening or randomization, unrelated to central neuropathic pain after SCI, that may confound the assessment of central neuropathic pain after SCI
•Major psychiatric disorders within 1 year prior to screening

Related studies

Not Yet RecruitingPhase 3

Efficacy and Safety of HSK16149 Capsule in the Treatment of Moderate and Severe Central Neuropathic Pain in China

NCT06422117 · Central Neuropathic Pain

COMPLETEDPhase 2

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

NCT01324232 · Central Neuropathic Pain, Multiple Sclerosis

Analgesic Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) for Central Neuropathic Pain in Multiple Sclerosis

NCT02059096 · Multiple Sclerosis With Central Neuropathic Pain

COMPLETEDPhase 4

Efficacy Of Pregabalin In Subjects With Post-Stroke Central Neuropathic Pain

NCT00313820 · Central Neuropathic Pain

EEG Predictors of Neuropathic Pain in SCI

NCT04665492 · Central Neuropathic Pain, Spinal Cord Injuries

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 21, 2024Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE3

Enrollment300

Start dateMar 2019

Last updatedOct 21, 2024

Condition

Central Neuropathic Pain

Locations shown

Chubu-Rosai Hospital

Aichi

Social Medical Corporation Daido Clinic

Aichi

Honmachi Clinic

Aichi

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 21, 2024Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions